PubRank

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Clinical Trial ID NCT02245867

PubWeight™ 0.83‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02245867

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Molecular mechanisms of amyloidosis. N Engl J Med 2003 7.75
2 Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005 5.64
3 Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995 5.51
4 High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004 4.05
5 A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997 2.66
6 Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002 1.58
7 Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008 1.54
8 Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000 1.49
9 Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 2002 1.39
10 Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 2003 1.11
11 In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol 1999 1.05
12 Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry 2007 0.98
13 Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res 2003 0.97
14 A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001 0.95
15 Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2012 0.92
16 Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry 2007 0.91
17 Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes. PLoS One 2015 0.85
Next 100